27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
As Insys Therapeutics Inc (NASDAQ:INSY) shifts from opioid therapies to cannabinoids and spray technology, one analyst sees an opportunity to buy in.
The Rating
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Janney analyst Yun Zhong assumed coverage with a Buy rating and cut his price target from $16 to $11.
The Thesis
Insys forecasted at least six New Drug Applications through 2022 for products spanning cannabinoids to epinephrine.
The firm specifically stands to profit from heightened naloxone opportunity. Many at the FDA and in the medical community demand increased commercial access to combat the opioid epidemic. Insys has developed a proprietary intranasal spray to reverse overdoses and plans to file its NDA next quarter after completing a requested juvenile toxicity study.
Prospects for co-prescription with medically necessary opioids further bolster the thesis, as does the FDA’s willingness to award high priority status to over-the-counter naloxone developers. The burdensome requisite study design may delay OTC revenue, though.
Apart from naloxone, Insys boasts opportunity in its epinephrine nasal spray, which could address the current EpiPen shortage.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
In cannabinoids, its manufacturing scale is empowering studies in diverse indications, from epilepsy and autism to PTSD and Prader-Willi syndrome.
“We believe the data from the cannabidiol (CBD) programs in 2019, if positive, could unlock significant upside potential for INSY shares, which should far exceed the downside risk,” Zhong wrote in a note.
Learn, connect or raise money at the leading event for connecting cannabis companies to investors.
As another catalyst, Insys is in talks to divest its SubSys, which suffers declining net revenue.
Price Action
At time of publication, Insys shares traded at $4.37.
Related Links:
12 NYSE- And NASDAQ-Listed Stocks With Cannabis Exposure
Piper Jaffray Loses Confidence In Insys Therapeutics, Downgrades Stock
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.